A meta-analysis on domestic irbesartan in the treatment of mild to moderate primary hypertension

Objective To explore the safety and efficacy of domestic irbesartan in patients with mild to moderate primary hypertension. Methods The outcomes of five blind, randomized, control clinical trials were quantitatively evaluated using meta-analysis. Losartan was used as control. Results There was no significant difference in lowering blood pressure between the irbesartan group and the losartan group (P = 0.06), but irbesartan had a slightly better efficacy. HR did not differ significantly after irbesartan therapy, as compared with the baseline (P = 0.88). The weighted mean difference of losartan was 1.77, 95%CI (0.11, 3.43), suggesting that heart rate was slightly declined after treatment with losartan. There was no significant difference between the two groups in the occurrence rate of adverse events (P = 0.99). Conclusion Irbesartan is safe and effective in lowering mild to moderate primary hypertension.